| Gene symbol | CCR5 | Synonyms | CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p21.31 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | C-C motif chemokine receptor 5 | ||||
| Gene symbol | tat | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001802.1 (5377..7970) | dbXrefs | |
| Description | Tat | ||||
| Gene symbol | vif | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001802.1 (4587..5165) | dbXrefs | |
| Description | Vif | ||||
| GTO ID | GTC3183 |
| Trial ID | NCT05540964 |
| Disease | HIV Infection |
| Altered gene | CCR5|tat|vif |
| Therapeutic/Target gene | Target gene |
| Therapy | Gene transfer |
| Treatment | AGT103-T |
| Recruitment status | Enrolling By Invitation |
| Title | An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact and Durability of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy(ART) in Participants With Human Immunodeficiency Virus(HIV) Previously Treated With AGT103-T |
| Year | 2022 |
| Country | United States |
| Company sponsor | American Gene Technologies International Inc. |
| Other ID(s) | AGT-HC-169 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||
|
|||||||||||